NO994185D0 - Chimeriske flavivirus vaksiner - Google Patents
Chimeriske flavivirus vaksinerInfo
- Publication number
- NO994185D0 NO994185D0 NO994185A NO994185A NO994185D0 NO 994185 D0 NO994185 D0 NO 994185D0 NO 994185 A NO994185 A NO 994185A NO 994185 A NO994185 A NO 994185A NO 994185 D0 NO994185 D0 NO 994185D0
- Authority
- NO
- Norway
- Prior art keywords
- protein
- prm
- chimeric flavivirus
- flavivirus vaccines
- expressed
- Prior art date
Links
- 241000710831 Flavivirus Species 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 241000710772 Yellow fever virus Species 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 229940051021 yellow-fever virus Drugs 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80744597A | 1997-02-28 | 1997-02-28 | |
US766498A | 1998-01-15 | 1998-01-15 | |
PCT/US1998/003894 WO1998037911A1 (en) | 1997-02-28 | 1998-03-02 | Chimeric flavivirus vaccines |
Publications (3)
Publication Number | Publication Date |
---|---|
NO994185D0 true NO994185D0 (no) | 1999-08-27 |
NO994185L NO994185L (no) | 1999-10-27 |
NO329693B1 NO329693B1 (no) | 2010-12-06 |
Family
ID=26677253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19994185A NO329693B1 (no) | 1997-02-28 | 1999-08-27 | Kimaerisk virus samt anvendelse derav, nukleinsyremolekyl og vaksinesammmensetning. |
Country Status (21)
Country | Link |
---|---|
EP (3) | EP2251036A1 (no) |
JP (2) | JP4504464B2 (no) |
KR (1) | KR100517323B1 (no) |
CN (1) | CN1187088C (no) |
AT (2) | ATE297757T1 (no) |
AU (1) | AU740961B2 (no) |
BR (1) | BR9807873A (no) |
CA (1) | CA2282790C (no) |
CZ (1) | CZ300172B6 (no) |
DE (2) | DE69830579T2 (no) |
DK (2) | DK0977587T3 (no) |
ES (2) | ES2244050T3 (no) |
HK (1) | HK1025743A1 (no) |
HU (1) | HU228705B1 (no) |
IL (4) | IL131600A0 (no) |
NO (1) | NO329693B1 (no) |
NZ (1) | NZ337522A (no) |
PL (1) | PL192957B1 (no) |
PT (2) | PT977587E (no) |
RU (1) | RU2209082C2 (no) |
WO (1) | WO1998037911A1 (no) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
IL139844A0 (en) | 1998-06-04 | 2002-02-10 | Us Gov Health & Human Serv | Nucleic acid vaccines for prevention of flavivirus infection |
US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US7009044B1 (en) * | 1999-06-04 | 2006-03-07 | The United States Of America As Represented By The Department Of Health And Human Services | HCV/BVDV chimeric genomes and uses thereof |
US7425437B2 (en) | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
AU1813901A (en) * | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
US6589531B1 (en) * | 2000-01-21 | 2003-07-08 | The Regents Of The University Of California | Recombinant yellow fever virus and method of use thereof |
CA2400182C (en) * | 2000-02-10 | 2011-06-28 | Alexander Pletnev | Full-length infectious cdna clones of tick borne flavivirus |
US7094411B2 (en) * | 2000-02-16 | 2006-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Avirulent, immunogenic flavivirus chimeras |
AU2007202304B2 (en) * | 2001-04-04 | 2010-03-18 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION | Nucleic acid vaccines for prevention of flavivirus infection |
FR2823222B1 (fr) * | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
US7740863B2 (en) | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
EP2305299B1 (en) | 2001-05-31 | 2017-03-01 | GlaxoSmithKline Biologicals SA | Chimeric alphavirus replicon particles |
PL371187A1 (en) | 2001-06-01 | 2005-06-13 | Acambis, Inc. | Chimeric flavivirus vectors |
US6682883B1 (en) * | 2001-07-19 | 2004-01-27 | Acambis, Inc. | Diagnosis of flavivirus infection |
MXPA04003692A (es) * | 2001-10-19 | 2005-04-08 | Acambis Inc | Metodos para prevenir y tratar la infeccion por flavivirus en animales. |
EP1461441A4 (en) * | 2001-11-26 | 2006-02-22 | Univ Queensland | FEEDING SYSTEM FOR FLAVIVIRUS VACCINES |
JP2005519639A (ja) | 2002-01-15 | 2005-07-07 | アカンビス インコーポレーティッド | フラビウイルスワクチン |
ES2427139T3 (es) * | 2002-06-20 | 2013-10-29 | Institut Pasteur | Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna |
EP1375512B1 (en) | 2002-06-20 | 2009-07-22 | Institut Pasteur | Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions |
EP1546176A4 (en) * | 2002-07-19 | 2006-01-11 | Univ Texas | METHODS AND COMPOSITIONS ASSOCIATED WITH ALTERED YELLOW FEVER VIRUS STEM |
KR101150584B1 (ko) | 2002-11-15 | 2012-06-27 | 사노피 파스테르 바이오로직스 씨오 | 웨스트 나일 바이러스 백신 |
CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
WO2005040390A1 (fr) * | 2003-07-21 | 2005-05-06 | Shanghai Tengen Biomedical Co., Ltd. | Vaccin recombine utilisant le virus de la fievre jaune comme vecteur |
CN1304579C (zh) * | 2003-07-21 | 2007-03-14 | 上海天甲生物医药有限公司 | 重组的以黄热病病毒为载体的疫苗 |
CN103088038B (zh) * | 2004-07-12 | 2015-06-24 | 美国天甲生物医药有限公司 | 黄病毒疫苗 |
WO2006044857A2 (en) | 2004-10-20 | 2006-04-27 | Acambis Inc. | Vaccines against japanese encephalitis virus and west nile virus |
WO2006067122A2 (en) | 2004-12-20 | 2006-06-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
CN101090966B (zh) | 2004-12-24 | 2012-07-04 | 财团法人阪大微生物病研究会 | 具有减毒日本脑炎病毒基因作为主链的减毒嵌合黄病毒 |
EP1874346B1 (en) | 2005-04-24 | 2014-06-25 | Sanofi Pasteur Biologics, LLC | Recombinant flavivirus vaccines |
WO2006120230A2 (en) | 2005-05-12 | 2006-11-16 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
BRPI0504945B8 (pt) | 2005-10-31 | 2022-08-02 | Fundacao Oswaldo Cruz | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. |
CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
KR101508390B1 (ko) | 2006-06-06 | 2015-04-08 | 크루셀 홀란드 비.브이. | 포도상구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도 |
EP2043681B1 (en) | 2006-07-14 | 2015-10-07 | Sanofi Pasteur Biologics, LLC | Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins |
FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
WO2008057550A2 (en) | 2006-11-07 | 2008-05-15 | Sanofi Pasteur Biologics Co. | Stabilization of vaccines by lyophilization |
WO2008094674A1 (en) * | 2007-01-31 | 2008-08-07 | Sanofi Pasteur Biologics Co. | Recombinant bicistronic flavivirus vectors |
EP2117588A4 (en) * | 2007-02-09 | 2011-05-04 | Sanofi Pasteur Biologics Co | VIRAL VECTORS AND METHODS OF USE |
BRPI0909820A2 (pt) | 2008-03-05 | 2015-08-11 | Sanofi Pasteur | Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima |
EA023888B1 (ru) * | 2008-03-14 | 2016-07-29 | Санофи Пастер Байолоджикс, Ллс | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
MY168959A (en) | 2012-07-24 | 2019-01-28 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
WO2014016362A1 (en) | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
JP2015531383A (ja) | 2012-10-03 | 2015-11-02 | サノフィ・パスツールSanofipasteur | 日本脳炎、麻疹、流行性耳下腺炎および風疹に対するワクチン接種 |
BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
EP4183411A1 (en) | 2013-03-15 | 2023-05-24 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
CN105246506A (zh) | 2013-06-21 | 2016-01-13 | 默沙东公司 | 登革病毒疫苗组合物及其使用方法 |
CN103352029A (zh) * | 2013-07-29 | 2013-10-16 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种乙脑/森林脑炎嵌合病毒及其应用 |
TW201620546A (zh) | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
SG11201704942QA (en) | 2014-12-22 | 2017-07-28 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
BR112017028212A2 (pt) | 2015-07-03 | 2018-09-11 | Sanofi Pasteur | vacinação concomitante contra dengue e febre amarela |
CN105400799B (zh) * | 2015-12-22 | 2018-12-28 | 成都生物制品研究所有限责任公司 | 一种乙脑/黄热嵌合病毒及其制备方法和应用 |
WO2017109698A1 (en) | 2015-12-22 | 2017-06-29 | Glaxosmithkline Biologicals Sa | Immunogenic formulation |
GB201716307D0 (en) * | 2017-10-05 | 2017-11-22 | Univ Leuven Kath | Chimeric yellow fever zika virus strain |
JP7313345B2 (ja) | 2017-10-05 | 2023-07-24 | サノフィ・パスツール | デング熱に対するブースターワクチン接種のための組成物 |
KR20190127605A (ko) * | 2018-05-04 | 2019-11-13 | 에스케이바이오사이언스(주) | 키메라 지카바이러스 백신 |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
IL298307A (en) | 2018-09-05 | 2023-01-01 | Takeda Vaccines Inc | Dengue fever vaccine unit dose and its administration |
US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
WO2020051328A1 (en) | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Assay for determining antibody response to dengue virus |
GB201814563D0 (en) * | 2018-09-07 | 2018-10-24 | Univ Leuven Kath | Chimeric flavivirus lyssavirus vaccines |
CN114555113A (zh) | 2019-08-16 | 2022-05-27 | 武田疫苗股份有限公司 | 用于预防登革热和甲型肝炎的方法 |
US20240076631A2 (en) | 2020-02-27 | 2024-03-07 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
CN113215116B (zh) * | 2021-05-11 | 2022-07-19 | 中国科学院动物研究所 | 基于朝阳病毒载体的嵌合病毒、疫苗及其应用 |
CN117751183A (zh) * | 2021-05-27 | 2024-03-22 | 迈凯恩技术有限公司 | 使用假病毒的抗体依赖性感染增强反应的评价方法 |
WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL91304A0 (en) * | 1988-08-20 | 1990-03-19 | Us Health | Recombinant vaccinia virus for prevention of disease caused by flavivirus |
ES2153223T3 (es) * | 1991-09-19 | 2001-02-16 | Us Health | Flavivirus quimericos y/o flavivirus de crecimiento restringido. |
-
1998
- 1998-03-02 CA CA2282790A patent/CA2282790C/en not_active Expired - Lifetime
- 1998-03-02 EP EP10005372A patent/EP2251036A1/en not_active Withdrawn
- 1998-03-02 ES ES98910103T patent/ES2244050T3/es not_active Expired - Lifetime
- 1998-03-02 DE DE69830579T patent/DE69830579T2/de not_active Expired - Lifetime
- 1998-03-02 PL PL335481A patent/PL192957B1/pl unknown
- 1998-03-02 WO PCT/US1998/003894 patent/WO1998037911A1/en active Application Filing
- 1998-03-02 AT AT98910103T patent/ATE297757T1/de active
- 1998-03-02 NZ NZ337522A patent/NZ337522A/en not_active IP Right Cessation
- 1998-03-02 BR BR9807873A patent/BR9807873A/pt not_active Application Discontinuation
- 1998-03-02 DE DE69841690T patent/DE69841690D1/de not_active Expired - Lifetime
- 1998-03-02 HU HU0002139A patent/HU228705B1/hu unknown
- 1998-03-02 CZ CZ0306499A patent/CZ300172B6/cs not_active IP Right Cessation
- 1998-03-02 ES ES05012770T patent/ES2345614T3/es not_active Expired - Lifetime
- 1998-03-02 PT PT98910103T patent/PT977587E/pt unknown
- 1998-03-02 RU RU99120696/14A patent/RU2209082C2/ru active
- 1998-03-02 DK DK98910103T patent/DK0977587T3/da active
- 1998-03-02 AU AU64431/98A patent/AU740961B2/en not_active Expired
- 1998-03-02 KR KR10-1999-7007904A patent/KR100517323B1/ko not_active IP Right Cessation
- 1998-03-02 AT AT05012770T patent/ATE468858T1/de active
- 1998-03-02 IL IL13160098A patent/IL131600A0/xx not_active IP Right Cessation
- 1998-03-02 EP EP05012770A patent/EP1625852B1/en not_active Expired - Lifetime
- 1998-03-02 DK DK05012770.3T patent/DK1625852T3/da active
- 1998-03-02 JP JP53790798A patent/JP4504464B2/ja not_active Expired - Lifetime
- 1998-03-02 PT PT05012770T patent/PT1625852E/pt unknown
- 1998-03-02 EP EP98910103A patent/EP0977587B1/en not_active Expired - Lifetime
- 1998-03-02 CN CNB988045567A patent/CN1187088C/zh not_active Expired - Lifetime
-
1999
- 1999-08-27 NO NO19994185A patent/NO329693B1/no not_active IP Right Cessation
-
2000
- 2000-08-09 HK HK00104982A patent/HK1025743A1/xx not_active IP Right Cessation
-
2008
- 2008-07-31 IL IL193170A patent/IL193170A/en not_active IP Right Cessation
-
2009
- 2009-10-28 JP JP2009247641A patent/JP2010057496A/ja active Pending
-
2010
- 2010-08-10 IL IL207517A patent/IL207517A0/en unknown
- 2010-08-10 IL IL207516A patent/IL207516A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0977587T3 (da) | Kimære flavivirus-vacciner | |
ATE397070T1 (de) | Klonierte genome von infektiösen hepatitis c viren und deren verwendungen | |
DE69231570T2 (de) | Chimäre und/oder wachstumgehemmte Flaviviren | |
DE68903165D1 (de) | Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein. | |
EP1554301A4 (en) | TETRAVALENT DENGUE VACCINE WITH A BLACK 30 NUCLEOTIDE DELETION IN 3'-UTR OF DENGUE TYPES 1,2,3 AND 4, OR ANTIGEN CHIMERAL DENGUE VIRUSES 1,2,3 AND 4 | |
DK0783321T3 (da) | VR-2332 viral nucleotidsekvens og fremgangsmåder til anvendelse | |
NO983946D0 (no) | Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner | |
WO2001021807A8 (en) | Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof | |
DE60034884D1 (de) | Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen | |
AUPR567401A0 (en) | Circovirus vaccines | |
NZ511168A (en) | Recombinant CELO virus and CELO virus DNA | |
FI893346A0 (fi) | Icke-reverterande rna-virus. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |